Cara Therapeutics (NASDAQ: CARA) reported Q2 EPS of ($0.58), $0.04 worse than the analyst estimate of ($0.54). Revenue for the quarter came in at $6.93 million versus the consensus estimate of $6.5 million.

For earnings history and earnings-related data on Cara Therapeutics (CARA) click here.